e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappa B and endothelin-1
Henno P., Maurey C., Danel C., Bonnette P., Souilamas R., Stern M., Delclaux C., Levy M., Israel-Biet D.
Source:
Eur Respir J 2009; 34: 1329-1337
Journal Issue:
December
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Henno P., Maurey C., Danel C., Bonnette P., Souilamas R., Stern M., Delclaux C., Levy M., Israel-Biet D.. Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappa B and endothelin-1. Eur Respir J 2009; 34: 1329-1337
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Role of endothelin-1 in endothelial dysfunction in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Pulmonary vascular involvement in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 28S-32S
Year: 2003
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Endothelial dysfunction in cystic fibrosis: imbalance NOS/arginase?
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007
Role of endothelin in lung fibrosis
Source: Eur Respir Rev 2008; 17: 145-150
Year: 2008
Blocking endothelin: breaking new ground
Source: Eur Respir Rev 2008; 17: 24-29
Year: 2007
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
The effect of mtTFA methylation in the pathogenesis of pulmonary vascular endothelial cell apoptosis of chronic obstructive pulmonary disease
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 17: 180-189
Year: 2001
Increased rho-kinase activity is related to pulmonary endothelial dysfunction in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis
Source: Eur Respir J 2012; 39: 141-148
Year: 2012
Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis
Source: Eur Respir J 2011; 39: 141-148
Year: 2012
Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients
Source: Eur Respir J 2010; 36: 682-683
Year: 2010
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept